June 7 (Reuters) - An experimental drug for rheumatoid arthritis developed by Johnson & Johnson and GlaxoSmithKline slowed joint damage and improved symptoms of the disease, meeting the main goals of a large, late stage trial, according to data released on Tuesday. In the study of 1,670 pat
Read more(Corrects paragraph one to show day of week Novartis said this was Monday, instead of Tuesday) * Novartis to seek approval after July following trial * Drug combo shrank tumours in 63 pct of patients in study * Combination already approved in skin cancer By John Miller
Read more(Adds details on dispute, paragraphs 3-7) By Lawrence Hurley WASHINGTON, June 6 (Reuters) - The U.S. Supreme Court on Monday declined to hear GlaxoSmithKline Plc's bid to throw out lawsuits by union health and welfare funds that said the company's misrepresentation of heart-related ri
Read moreWASHINGTON, June 6 (Reuters) - The U.S. Supreme Court on Monday declined to hear GlaxoSmithKline Plc's bid to throw out lawsuits by union health and welfare funds that said the company's misrepresentation of heart-related risks of its diabetes medication Avandia caused them to pay too much for th
Read more* Tivicay to be used as first-line HIV treatment * 100,000 more Botswanans to receive drug treatment (Adds launch in Gaborone, comment from UNAIDS and U.S. ambassador) By Ben Hirschler LONDON, June 3 (Reuters) - An HIV drug first approved less than three years ago is being rol
Read moreLONDON, June 3 (Reuters) - An HIV drug first approved less than three years is to be rolled out in Botswana as a first-line core medicine to treat newly diagnosed patients under a contract agreed between the government and ViiV Healthcare. ViiV, which is majority-owned by GlaxoSmithKline, s
Read moreEditor: Sonya Hepinstall +44 207 542 3479 Global Picture Desk: +65 6870 3775 Global Graphics Desk: +65 6870 3595 (All times GMT / ET) Receive this schedule by email: http://mediaexpress.reuters.com TOP STORIES ECB keeps rates unchanged, may raise inflatio
Read more* U.S. filing by end 2016 vs first half 2018 seen previously * Rivals in triple drug space include AstraZeneca, Novartis (Adds more details on competitive market) By Ben Hirschler LONDON, June 2 (Reuters) - GlaxoSmithKline moved to consolidate its lead in a new class of three-
Read more(ShareCast News) - GlaxoSmithKline has, after discussions with the US regulator, accelerated the new drug application for its daily closed triple therapy for chronic obstructive pulmonary disease (COPD). GSK and its partner in the drug, Innoviva, now expect to make the US regulatory submission befor
Read moreLONDON, June 2 (Reuters) - GlaxoSmithKline said on Thursday it now expects to file its new three-in-one inhaled lung drug for U.S. approval by the end of 2016, rather than the first half of 2018 as previously expected, in a boost for its pivotal respiratory business. The so-called "closed t
Read moreLONDON, June 2 (Reuters) - The global pharmaceuticals industry remains open to corruption abuse, despite a raft of scandals in recent years, with both companies and governments failing to tackle the issue adequately, according to Transparency International. The anti-corruption advocacy grou
Read more